Skip Main Navigation
Page Content
This event has ended

Save This Event

Event Saved

Image and video hosting by TinyPic

Evaluating Life Science Companies for Investment

Biotech Connection Singapore (BCS)

Tuesday, 6 September 2016 from 18:30 to 21:00 (Singapore Standard Time Singapore Time)

Evaluating Life Science Companies for Investment

Ticket Information

Type End Quantity
General Admission Ended Free  

Share Evaluating Life Science Companies for Investment

Event Details

event logo 

Medical devices, biopharmaceuticals and healthcare sectors are growing rapidly, fueled by an influx of smart investment dollars. How do investors assess life science startups before committing to an investment? What are on their checklists for determining risks and returns? In this panel discussion, we bring together experienced investors across the funding landscape, from venture capital and angel investing, to multinational corporations and government organisations. Join us to find out what these investors look for when evaluating life science companies and how you can improve your odds of getting funded.

 

 

Programme Details


Date: Tues, Sep 6th 2016

 

Venue: Breakthrough Theatrette, Matrix Level 4, Biopolis

             30 Biopolis Street, Singapore 138671

 

 

6.30 - 7.00pm              Registration 

7.00 - 7.05pm              Introduction to BCS and A*StartCentral

7.05 - 8.05pm              Speaker Introduction & Panel Discussion

8.05 - 9.00pm              Networking reception with light refreshments

 

 

Speaker Biographies

 

Moderator:

 

SnehalSnehal Patel, M.D., J.D.

Co-Founder & Director

MyDoc Pte. Ltd.

Dr Patel co-founded MyDoc and is also a Managing Director of Saena Partners, a Singapore-based investment company. Previously, he was a Senior Vice President at Chandler Corporation, a multi-billion dollar investment fund based in Singapore. In this role, he founded and led the investment team responsible for investing in healthcare businesses in South and Southeast Asia. His responsibilities included leading the on-the-ground incubation and early growth of a regional healthcare chain, as well as serving on the boards of several early-stage healthcare and education businesses throughout the region. Prior to moving to Singapore in 2008, Dr Patel practiced law at Cravath, Swaine & Moore, and LLP in New York. He received an MD from the Columbia University College of Physicians and Surgeons and a JD from Columbia Law School. Upon graduation, he served as a Clinical Fellow at the Harvard Medical School, and was offered a Fulbright scholarship to study the differences between the Singaporean and US healthcare systems. Dr Patel was a featured speaker at the 2011 Milken Global Conference and is a member of the Society of Kauffman Fellows.


 

 

Panelists:

 

CarolynCarolyn Ng, Ph.D.

Investment Director

Vertex Healthcare Venture Capital

Carolyn Ng is the Investment Director of Vertex Healthcare Ventures, the VC arm of Temasek Holdings specializing in early stage life sciences investments. She is based in the Singapore office, where she evaluates venture investment opportunities across biotechnology and medical devices sectors globally. Prior to joining Vertex, Carolyn was a Consultant at Deallus Consulting, a specialized life sciences strategy consulting firm. While at Deallus, she led multiple consulting projects for large pharmaceutical companies supporting due diligence of in-/out-licensing opportunities, analyzing competitive landscapes of emerging classes of therapeutics, and formulating go-to-market strategies for Asian markets. Carolyn was also a molecular oncology research scientist in YLL School of Medicine, the National University of Singapore. She was a recipient of the NUS Graduate School for Integrative Sciences and Engineering PhD scholarship, and holds the patent of a novel small molecule nuclear receptor activator indicated for the treatment of neuroblastoma.

 

Carolyn holds a PhD in Cancer Molecular Biology from the NUS Graduate School for Integrative Sciences and Technology, and also holds a BS (Pharmacy) (Honours) degree from the National University of Singapore.


 

StefanStefan Hart, Ph.D.

Director, New Ventures Singapore/SEA/India

Johnson & Johnson Innovation

Dr Stefan Hart is Director, New Ventures Singapore/SEA/India at Johnson & Johnson Innovation. In this role he deepens Johnson & Johnson Innovation’s network with innovators and entrepreneurs in the regional life science ecosystem, and sources and establishes collaboration and investment opportunities for the pharma, medical devices and diagnostics, and consumer sector of J&J. 

Previously Stefan worked at Roche as the Manager of Pre-clinical Academic Alliance. In this role, he directed key external collaborations. Prior to that, Stefan was a Senior Scientist at S*BIO Pte Ltd. In this role, Stefan acted as a core member of Pracritinib drug development team. He led the pre-clinical development and successfully implemented the clinical biomarker strategy.

Stefan trained as an engineer in biotechnology at the University for Applied Sciences Weihenstephan (Freising, Germany). He received his Ph.D. research at the Max-Planck-Institute for Biochemistry, where his work focused on the transactivation of the EGFR by G protein-coupled receptors in human cancer, and resulted in significant publications that led to the MPIB Junior Research Award in 2004. Stefan did his postdoctoral research at the Institute for Medical Biology (IMB), Singapore where he launched the Singapore OncoGenome Project. Stefan is also the author of 25 publications in peer reviewed scientific journals and of 2 patents.

 

 

Wai ChiewChik Wai Chiew, MBA

Executive Vice President, Commercialisation Division

Exploit Technologies Pte Ltd

As Executive Vice President, Commercialisation at ETPL, Wai Chiew leads an experienced team of licensing and business development professionals to originate and manage an impactful portfolio of deep science projects based on A*STAR’s technologies and funding.

Prior to assuming his current position at ETPL, Wai Chiew has enjoyed various public and private sector positions including Singapore Economic Development Board (EDB), Temasek Holdings and Tembusu Partners. He has extensive global experience in strategic planning; business development; corporate governance; organisational transformation; venture incubation; and investment management. Wai Chiew has also mentored business founders and served on multiple corporate boards across Asia.

Wai Chiew holds a BA (Economics) from Cambridge University; MA (International and Development Economics) from Yale University and EMBA from Cheung Kong Graduate School of Business. 

 

 

SridalSridhar Gopal

Business Development & New Product Planning Director, Japan Asia Pacific

AbbVie Inc

Sridhar Gopal has a wealth of experience in Business Development, M&A, and Licensing across international markets. Currently Sridhar leads Business Development and New Product Planning for AbbVie for JAPAC. Prior to AbbVie, Sridhar spent close to a decade in Astra Zeneca, in US and Asia, in Global & Regional roles in Business Development including Evaluations, Transactions and Alliance Management.

Sridhar has successfully closed several varied deals including Acquisitions, licensing’s, co-marketing, co promotions, divestments across markets. Among Sridhar’s experiences, he has led teams pursuing diverse Global Strategic projects like Branded Generics, Biosimilars, and Orphan Drugs.

 

Event Partners

 

 

 

Event Sponsor

 

 

 

 

 

 

Brought to you by

BCS Logo

 

 

 


Do you have questions about Evaluating Life Science Companies for Investment? Contact Biotech Connection Singapore (BCS)

When & Where


Breakthrough Theatrette
Matrix Building level 4
30 Biopolis Street
Singapore, Singapore 138671
Singapore

Tuesday, 6 September 2016 from 18:30 to 21:00 (Singapore Standard Time Singapore Time)


  Add to my calendar

Organiser

Biotech Connection Singapore (BCS)

Biotech Connection Singapore (BCS) is a non-profit organization that aims to promote life science entrepreneurship in Singapore. Established in 2014, BCS is the Singapore chapter of a global network, with chapters in biotech hubs such as San Francisco, Boston, and Los Angeles. BCS serves as a platform to foster interaction between academia, industry and business in the biomedical and healthcare fields. We connect innovators with industry resources to develop ideas into successful commercial products. We engage our growing community of members by organizing educational events, providing consulting services and enabling communications to our members at large. Find out more at www.biotechconnection-sg.org.

  Contact the Organiser

Interested in hosting your own event?

Join millions of people on Eventbrite.

Please log in or sign up

In order to purchase these tickets in installments, you'll need an Eventbrite account. Log in or sign up for a free account to continue.